We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Sets Final Trial Requirements for Drugs for Complicated Intra-abdominal Infections
FDA Sets Final Trial Requirements for Drugs for Complicated Intra-abdominal Infections
Trials of drugs targeting complicated intra-abdominal infections should use only drugs that are standard of care as active comparators, the FDA says, and studies should minimize the use of outside antibiotics in trial subjects as much as possible to produce clear, definitive trial results.